Register Login

Precision BioSciences (DTIL)

(90% Positive) Precision BioSciences (DTIL) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:11 p.m.

    📋 Precision BioSciences (DTIL) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 16:11:45

    Event Type: Clinical Trial Update

    Event Details:

    Precision BioSciences (DTIL) Announces Clinical Trial Update Precision BioSciences (DTIL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial, expected
    • Diseases/Conditions: our global Phase 1/2a ELIMINATE-B trial, DMD ente
    • Clinical Stage: Phase 1
    • Collaboration: DTIL
    • Updated Timeline: Q1 2026, December 31, 2025
      • expected in 2026
      • expected by year end 2026
      • targeting muscle satellite cells.Following clearance of the investigational new drug (IND) application, the FUNCTION-DMD Phase 1/2 clinical trial is expected to dose the first patient in late-Q1 or early-Q2 2026

    🔬 Clinical Development Pipeline (Precision BioSciences):

    Product Type Development Stage Therapeutic Area Source
    PBGENE-HBV BIOLOGICAL Preclinical Chronic HBV Infection ClinicalTrials.gov
    Nirogacestat DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    PBCAR269A GENETIC Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    PBCAR20A GENETIC Phase PHASE1 Non-Hodgkin's Lymphoma, Relapsed ClinicalTrials.gov
    PBCAR19B GENETIC Phase PHASE1 CD19 Expressing Malignancies ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Precision BioSciences
    • Ticker Symbol: DTIL

Search

News categories